Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) with Low-Dose XXXX and @entity632 in Gastric Peritoneal @entity3 .

@entity1 @entity632 @entity298 @entity5 @entity900 @entity3 @entity902 @entity356
BACKGROUND: Pressurized intraperitoneal aerosol chemotherapy (PIPAC) is a novel technique of intraperitoneal chemotherapy. First results obtained with PIPAC in @entity1 with advanced peritoneal @entity3 (PM) from @entity356 ( @entity356 ) are presented. METHODS: Retrospective analysis: Sixty PIPAC were applied in 24 consecutive @entity1 with PM from @entity356 . 67  % @entity1 had previous surgery, and 79  % previous @entity902 -based systemic chemotherapy. Mean @entity298 Index (PCI) of 16        10 and 18/24 @entity1 had signet-ring @entity356 . @entity900 7.5  mg/m(2) and @entity632 1.5  mg/m(2) were given for 30  min at 37    C and 12  mmHg at 6  week intervals. Outcome criteria were survival, adverse events, and histological @entity5 response. RESULTS: Median follow-up was 248  days (range 105-748), and median survival time was 15.4  months. Seventeen @entity1 had repeated PIPAC, and objective @entity5 response was observed in 12 (12/24   =   50  %): no vital @entity5 cells   =   6, major pathological response   =   6, minor response   =   3. Postoperative adverse events   >   CTCAE 2 were observed in 9 @entity1 (9/24, 37.5  %). In 3/17 @entity1 , a later PIPAC could not be performed due to non-access. Two @entity1 (ECOG 3 and 4) died in the hospital due to disease progression. CONCLUSION: PIPAC with low-dose @entity900 and @entity632 was safe and induced objective @entity5 regression in selected @entity1 with PM from recurrent, @entity902 -resistant @entity356 . First survival data are encouraging and justify further clinical studies in this indication.
